Drug trial aims to shield unborn babies from dangerous blood condition
NCT ID NCT06435845
Summary
This study tested an investigational drug called RLYB212, given to pregnant women at higher risk of developing an immune response that can harm their baby's platelets. The main goals were to check the drug's safety and how it moves through the body in both the mother and baby. The trial was terminated early and only enrolled one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333, Netherlands
-
Oslo University Hospital- Ullevål
Oslo, Oslo County, 0450, Norway
-
Södersjukhuset
Stockholm, Stockholm County, 118 83, Sweden
Conditions
Explore the condition pages connected to this study.